Pharming Group N.V. (PHAR) P/E Ratio History
Historical price-to-earnings valuation from 2020 to 2025
Loading P/E history...
PHAR Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Pharming Group N.V. (PHAR) trades at a price-to-earnings ratio of 300.0x, with a stock price of $12.00 and trailing twelve-month earnings per share of $0.04.
The current P/E is 11% above its 5-year average of 269.7x. Over the past five years, PHAR's P/E has ranged from a low of 27.8x to a high of 1812.5x, placing the current valuation at the 80th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, PHAR trades at a 1244% premium to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, PHAR commands a significant premium over the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PHAR DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PHAR P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 9.9Lowest | -Best | +68% | |
| $9B | 43.4 | -Best | +128% | |
| $39B | 127.0 | -Best | +207%Best | |
| $10B | 30.1 | -Best | -19% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
PHAR Historical P/E Data (2020–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $17.67 | $0.03 | 589.0x | +118% |
| FY2025 Q3 | $14.50 | $0.01 | 1812.5x | +572% | |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $11.03 | $0.14 | 78.8x | -71% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $9.84 | $0.34 | 28.8x | -89% |
| FY2022 Q2 | $8.76 | $0.30 | 29.0x | -89% | |
| FY2022 Q1 | $8.99 | $0.22 | 40.6x | -85% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $8.94 | $0.32 | 27.8x | -90% |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $11.27 | $0.40 | 28.4x | -89% |
| FY2021 Q1 | Wed Mar 31 2021 00:00:00 GM | $12.83 | $0.46 | 28.1x | -90% |
| FY2020 Q4 | $15.20 | $0.45 | 33.6x | -88% |
Average P/E for displayed period: 269.7x
See PHAR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PHAR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PHAR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPHAR — Frequently Asked Questions
Quick answers to the most common questions about buying PHAR stock.
Is PHAR stock overvalued or undervalued?
PHAR trades at 300.0x P/E, near its 5-year average of 269.7x. The 80th percentile ranking places valuation within normal historical bounds.
How does PHAR's valuation compare to peers?
Pharming Group N.V. P/E of 300.0x compares to sector median of 22.3x. The premium reflects expected growth above peers.
What is PHAR's PEG ratio?
PHAR PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2020-2025.